(alphaS)-alpha-氨基-N-[(1R)-1-[(3aS,4S,6S,7aR)-六氢-3a,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐
Bortezomib intermediates II
硼替佐米中间体;硼替佐米中间体2;(alphaS)-alpha-氨基-N-[(1R)-1-[(3aS,4S,6S,7aR)-六氢-3a,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐;(ALPHAS)-ALPHA-氨基-N-[(1R)-1-[(3AS,4S,6S,7AR)-六氢-3A,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐硼;替佐米中间体2;硼替佐米中间体I 硼替佐米中间体;硼替佐米中间体2;(alphaS)-alpha-氨基-N-[(1R)-1-[(3aS,4S,6S,7aR)-六氢-3a,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐;(ALPHAS)-ALPHA-氨基-N-[(1R)-1-[(3AS,4S,6S,7AR)-六氢-3A,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐硼;替佐米中间体2;硼替佐米中间体I 展开
205393-21-1
C12H11BrO3
283.12
中文名称 (alphaS)-alpha-氨基-N-[(1R)-1-[(3aS,4S,6S,7aR)-六氢-3a,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐
中文别名 硼替佐米中间体;硼替佐米中间体2;(alphaS)-alpha-氨基-N-[(1R)-1-[(3aS,4S,6S,7aR)-六氢-3a,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐;(ALPHAS)-ALPHA-氨基-N-[(1R)-1-[(3AS,4S,6S,7AR)-六氢-3A,5,5-三甲基-4,6-甲桥-1,3,2-苯并二氧硼烷-2-基]-3-甲基丁基]苯丙酰胺盐酸盐硼;替佐米中间体2;硼替佐米中间体I
英文名称 Bortezomib intermediates II
英文别名 Benzenepropanamide, a-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-,hydrochloride (1:1), (aS)-;Benzenepropanamide, a-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-m;BORTEZOMIB INTERMEDIATES II;N-{(1R)-3-Methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]dec-4-yl]butyl}-L-phenylalaninamide hydrochloride (1:1);(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide hydrochloride;(αS)-α-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-benzenepropanamide Monohydrochloride;Bortezomib Intermediate II;N-[(1S)-1-benzyl-2-({(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.0~2,6~]dec-4-yl]butyl}amino)-2-oxoethyl];Bortezomib intermediates I;(S)-2-amino-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamide hydrochloride;AK162832;Bortezomib Intermediate 2;393A211;Benzenepropanamide, alpha-amino-N-[(1R)-1-[(3aS,4S,6S,7;(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol;A879572;AKOS024462775;(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-benzenepropanamide Monohydrochloride;Benzenepropanamide, alpha-amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]-, hydrochloride (1:1), (alphaS)-;DS-7916;C73889;(2S)-2-amino-N-[(1R)-3-methyl-1-[(1S, 2S, 6R, 8S)-2, 9, 9-trimethyl-3, 5-dioxa-4-boratricyclo[6.1.1.02, 6]decan-4-yl]butyl]-3-phenylpropanamide;hydrochloride;(S)-2-amino-N-((R)-3-methyl-1-((3aS,4S,6S,7aR)-3a,5,5-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)-3-phenylpropanamidehydrochloride;AC-24854;(alphaS)-alpha-Amino-N-[(1R)-1-[(3aS,4S,6S,7aR)-hexahydro-3a,5,5-trimethyl-4,6-methano-1,3,2-benzodioxaborol-2-yl]-3-methylbutyl]benzenepropanamide Hydrochloride (Bortezomib Intermediate II);205393-21-1;(2S)-2-amino-N-[(1R)-3-methyl-1-[(1S,2S,6R,8S)-2,9,9-trimethyl-3,5-dioxa-4-boratricyclo[6.1.1.02,6]decan-4-yl]butyl]-3-phenylpropanamide;hydrochloride;(2S)-2-AMINO-N-[(1R)-3-METHYL-1-[(1S,2S,6R,8S)-2,9,9-TRIMETHYL-3,5-DIOXA-4-BORATRICYCLO[6.1.1.0(2),?]DECAN-4-YL]BUTYL]-3-PHENYLPROPANAMIDE HYDROCHLORIDE
CAS No. 205393-21-1
分子式 C12H11BrO3
分子量 283.12
象形图
警示语
Class
警告声明
UNub
危险声明
Packing Group
搜索质检报告(COA)
搜索MSDS